Company: REVB
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034584
Chunk: 291

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 8
Chunk 291
---
 net

    56,332

    65,084

    Total assets
     
    $
    6,622,049

    $
    12,212,609

    LIABILITIES AND STOCKHOLDERS’ EQUITY

    Current liabilities:

    Accounts payable
     
    $
    783,621

    $
    1,359,898

    Accrued expenses

    1,127,800

    1,152,460

    Deferred underwriting commissions

    —

    2,911,260

    Warrant liability

    2,246

    141,276

    Total current liabilities

    1,913,667

    5,564,894

    Total liabilities

    1,913,667

    5,564,894

    Commitments and Contingencies (Note 4)

    Stockholders’ equity:

    Common Stock, $0.001 par value; 500,000,000 shares authorized at December 31, 2024 and December 31, 2023 and 522,223 and 16,484 issued and outstanding at December 31, 2024 and December 31, 2023, respectively

    522

    16

    Additional paid-in-capital

    45,213,498

    32,114,801

    Accumulated deficit

    (40,505,638
    )

    (25,467,102
    )

    Total stockholders’ equity

    4,708,382

    6,647,715

    Total liabilities and stockholders’ equity
     
    $
    6,622,049

    $
    12,212,609

See accompanying notes to the consolidated financial statements.

 F-4

REVELATION BIOSCIENCES, INC.

Consolidated Statements of Operations

    Year EndedDecember 31,

    2024

    2023

    Operating expenses:

    Research and development
     
    $
    3,548,996

    $
    4,145,902

    General and administrative

    4,426,113

    4,510,762

    Total operating expenses

    7,975,109

    8,656,664

    Loss from operations

    (7,975,109
    )